
Simone Krebs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7137804/publications.pdf Version: 2024-02-01



SIMONE KDERS

#	Article	IF	CITATIONS
1	Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of Nuclear Medicine, 2014, 55, 1248-1252.	5.0	197
2	Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma. Molecular Therapy, 2016, 24, 354-363.	8.2	72
3	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clinical Cancer Research, 2019, 25, 6939-6947.	7.0	69
4	T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but alsoÂrecognize interleukin-13Rα1. Cytotherapy, 2014, 16, 1121-1131.	0.7	68
5	Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 677-685.	6.4	44
6	IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron. Cancer Imaging, 2018, 18, 51.	2.8	36
7	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36
8	Pharmacokinetic Assessment of ¹⁸ F-(2 <i>S,</i> 4 <i>R</i>)-4-Fluoroglutamine in Patients with Cancer. Journal of Nuclear Medicine, 2020, 61, 357-366.	5.0	23
9	Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3047-3057.	6.4	19
10	Genetically Modified T Cells to Target Glioblastoma. Frontiers in Oncology, 2013, 3, 322.	2.8	16
11	MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI. Clinical Imaging, 2018, 52, 193-199.	1.5	14
12	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. Annals of Lymphoma, 2021, 5, 15-15.	4.5	13
13	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. Journal of Nuclear Medicine, 2019, 60, 879-881.	5.0	11
14	lgG4-Related Kidney Disease in a Patient With History of Breast Cancer. Clinical Nuclear Medicine, 2016, 41, e388-e389.	1.3	10
15	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3940-3950.	6.4	8
16	Lower-Extremity Pseudomyogenic Hemangioendothelioma on Bone Scintigraphy and PET/CT. Clinical Nuclear Medicine, 2017, 42, 383-385.	1.3	7
17	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report. Frontiers in Oncology, 2017, 7, 284.	2.8	7
18	CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773.	2.8	7

SIMONE KREBS

#	Article	IF	CITATIONS
19	Patient Size-Dependent Dosimetry Methodology Applied to ¹⁸ F-FDG Using New ICRP Mesh Phantoms. Journal of Nuclear Medicine, 2021, 62, 1805-1814.	5.0	7
20	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
21	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	5.0	5
22	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	6.4	4
23	Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. Neuro-Oncology Advances, 2020, 2, vdaa050.	0.7	3
24	Cell carriers to attack glioma. Cytotherapy, 2014, 16, 871-872.	0.7	0
25	IM-02 * A scFv-BASED CAR TO REDIRECT T CELLS TO IL13RÂ2-POSITIVE PEDIATRIC GLIOMA. Neuro-Oncology, 2015, 17, iii15-iii15.	1.2	0